Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-09-28 am EDT
3480.00 JPY   +1.40%
09/09Japan's Nikkei ends week on a high in hawkish climate
RE
09/08Japanese stocks gain as investors digest cenbank decisions
RE
09/08Chugai Pharmaceutical : Summary
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S.

08/09/2022 | 10:01am EDT

Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Japan, hereafter Chugai) announced that Chugai, Roche and Genentech (collectively 'the Companies') have entered into a settlement agreement with Fresenius Kabi USA, LLC (hereafter, Fresenius) on August 5, 2022 relating to the patent lawsuit filed by the Companies on March 19, 2020. In the lawsuit, the Companies alleged that the submission of an Abbreviated New Drug Application ('ANDA') by Fresenius for a generic version of Alecensa (generic name: alectinib, an ALK inhibitor, anti-cancer agent) to the U.S. Food and Drug Administration infringed Chugai's patents in the U.S. (Nos. 9,126,931; 9,440,922; 9,365,514 and 10,350,214) under the framework of the Drug Price Competition and Patent Term Restoration Act (known as Hatch-Waxman Act). In accordance with the settlement agreement, the Companies and Fresenius will take steps to withdraw the lawsuit.

Patent Infringement Lawsuit to be withdrawn

Lawsuit filed at the United States District Court for the District of Delaware

Dates of Complaint: March 19, 2020 (U.S. Eastern Standard Time)

Defendant: Fresenius Kabi USA, LLC

Patents in suit: U.S. Patent Nos. 9,126,931; 9,440,922; 9,365,514 and 10,350,214

The impact on the consolidated financial results for the fiscal year ending December 2022 of Chugai is expected to be negligible.

Contact:

Media

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Investors

Corporate Communications Dept.

Takayuki Sakurai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD 1.40% 3480 Delayed Quote.-8.11%
FRESENIUS SE & CO. KGAA 0.28% 21.64 Delayed Quote.-38.98%
ROCHE HOLDING AG 3.69% 324.15 Delayed Quote.-17.54%
All news about CHUGAI PHARMACEUTICAL CO., LTD
09/09Japan's Nikkei ends week on a high in hawkish climate
RE
09/08Japanese stocks gain as investors digest cenbank decisions
RE
09/08Chugai Pharmaceutical : Summary
PU
08/24Roche's Japanese Unit Obtains Approval For Anticancer Medication
MT
08/24Chugai Pharmaceutical : Obtains Regulatory Approval for POLIVY for Additional Indication o..
PU
08/22Chugai Pharmaceutical : and Noile-Immune Biotech Enter into a License Agreement for Noile-..
PU
08/15Chugai Pharmaceutical : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl..
PU
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/10Chugai Pharmaceutical : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C..
PU
More news
Financials
Sales 2022 1 209 B 8 346 M 8 346 M
Net income 2022 360 B 2 485 M 2 485 M
Net cash 2022 529 B 3 650 M 3 650 M
P/E ratio 2022 15,8x
Yield 2022 2,31%
Capitalization 5 646 B 38 982 M 38 982 M
EV / Sales 2022 4,23x
EV / Sales 2023 4,68x
Nbr of Employees 7 664
Free-Float 38,0%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 432,00 JPY
Average target price 4 470,00 JPY
Spread / Average Target 30,2%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-8.11%38 982
JOHNSON & JOHNSON-3.58%433 657
ELI LILLY AND COMPANY11.32%295 599
ROCHE HOLDING AG-17.54%259 622
ABBVIE INC.4.67%250 575
PFIZER, INC.-25.33%247 449